The Desmoid Tumor Research Foundation

About DTRF

News & Updates

Stay Up to Date

Join The DTRF Newsletter

Join the Clinicians & Researchers Newsletter

OGSIVEO FDA-Approval Featured Image

Featured News

FDA APPROVES OGSIVEO™ (NIROGACESTAT), AS THE FIRST MEDICAL THERAPY FOR THE TREATMENT OF ADULTS WITH PROGRESSING DESMOID TUMORS.

Read More about FDA APPROVES OGSIVEO™ (NIROGACESTAT), AS THE FIRST MEDICAL THERAPY FOR THE TREATMENT OF ADULTS WITH PROGRESSING DESMOID TUMORS.

Filter by:

Jeanne Whiting, DTRF Executive Director Emeritus, and Lynne Hernandez, DTRF Executive Director

November 14, 2023

DTRF Leadership Team Attends CTOS 2023

Read More about DTRF Leadership Team Attends CTOS 2023

November 10, 2023

2023 DTRF Research Grants

Read More about 2023 DTRF Research Grants

2023 DTRF "Together We Will" Weekend

November 3, 2023

DTRF Hosts the 2023 “Together We Will” Weekend in Philadelphia

Read More about DTRF Hosts the 2023 “Together We Will” Weekend in Philadelphia

October 30, 2023

Reflections From Jeanne Whiting, Our Retiring Executive Director And DTRF’s Co-Founder

Read More about Reflections From Jeanne Whiting, Our Retiring Executive Director And DTRF’s Co-Founder

October 1, 2023

Ten New ICD-10-CM Diagnosis Codes For Desmoid Tumors Go Into Effect on October 1, 2023, in the United States.

Read More about Ten New ICD-10-CM Diagnosis Codes For Desmoid Tumors Go Into Effect on October 1, 2023, in the United States.

September 30, 2023

Desmoid Tumor Awareness Month 2023 Comes To A Close

Read More about Desmoid Tumor Awareness Month 2023 Comes To A Close